Analysis of IBD Biologics public use with active Bio-Manguinhos/Fiocruz Productive Development Partnerships agreements (2018-2022)

Julianna Varela; Thaís Catão; Amanda Marques; Eliane Santos; Bruna Veras; Jenifer Paula; Letícia Lignani

doi:10.35259/isi.2026_76196

January 1, 2026Open Access

Analysis of IBD Biologics public use with active Bio-Manguinhos/Fiocruz Productive Development Partnerships agreements (2018-2022)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the public use of IBD biologics during the partnerships between Bio-Manguinhos and Fiocruz.
Analysis of IBD biologics usage from 2018 to 2022.
Involvement in an international symposium organized by Bio-Manguinhos.
Findings presented at the International Symposium on Immunobiologicals.

Implication

Conference presentation analyzes public use of IBD biologics, indicating partnerships in biotechnology.

Abstract

Os autores externos submeteram sua publicação para apresentação de trabalho no evento 'International Symposium on Immunobiologicals', que foi coordenado e organizado pelo Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), da Fundação Oswaldo Cruz.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varela et al. (2026) studied this question.

synapsesocial.com/papers/69fece1db9154b0b82875d0d https://doi.org/10.35259/isi.2026_76196

View Full Paper

Ask AI

Bookmark

Share

Analysis of IBD Biologics public use with active Bio-Manguinhos/Fiocruz Productive Development Partnerships agreements (2018-2022)

Key Points

Implication

Abstract

Discussion

Cite This Study

Analysis of IBD Biologics public use with active Bio-Manguinhos/Fiocruz Productive Development Partnerships agreements (2018-2022)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading